|
The
resultant tumors were
allowed to grow for eight days. The test animals were divided
into two groups and fed a normal diet. Half of them, however,
were also given 1.1 mg of rubidium carbonate by mouth. After
thirteen days, the mice were killed and measurements were taken
of the tumor growth. Researchers found that the tumors in the
mice that had been given rubidium carbonate were only 9 percent
as large as those animals that had not been given the mineral.
In addition, the mice who had been administered the rubidium
showed none of the ravages normally associated with cancer.
Dr. Marilyn
Tufte of the Department of Biology at the University of
Wisconsin in Platteville conducted a second series of tests in
which mice received subcutaneous implants of colon carcinoma.
After the tumors were established, cesium carbonate, zinc
gluconate and vitamin A were administered to the test animals.
Dr. Tufte observed a 97 percent reduction in tumor growth using
this approach.
Dr. A.
Messiha and Dr F.S. El Domeiri of the Texas Tech University
Medical School at Lubbock conducted a series of experiments in
1981 in which mice were implanted with Sarcoma-I tumors and then
administered cesium salts. Their research demonstrated that this
form of the mineral was the most effective for both suppressing
the growth of tumors and shrinking them.
Despite
their encouraging results, the animal experiments, however, were
only a start. Therapies that show promise in animal tests do not
always prove effective in humans. The next step, therefore, was
to test the High pH Therapy in humans.
HUMAN TRIALS
A series of
U.S. clinical trials of the High pH Therapy were initiated in
1981. Dr. Brewer described the results of one of these trials in
a 1984 article published in the journal, Pharmacological
Biochemistry and Behavior. They were, to say the least,
astounding.
In the
abstract of the article, Dr. Brewer writes:
“Tests have been carried out on
over 30 humans. In each case the tumor masses disappeared. Also
all pains and effects associated with cancer disappeared within
12 to 36 hours; the more chemotherapy and morphine the patient
had taken, the longer the withdrawal period.”
Another
human trial had similar results. That U.S. trial involved 50
cancer patients. All but three of the patients suffered from
generalized metastatic disease, and all but three had received
various standard cancer therapies such as surgery, radiation and
chemotherapy. All of the patients were considered terminal.
Due to
their poor condition at the time the High pH Therapy was
initiated, thirteen of the initial group died within 14 days –
some only two days after arrival. Since these patients had
exhausted all other avenues of treatment prior to initiating the
High pH Therapy, this result was not particularly surprising.
Yet even among the patients for whom the High pH Therapy simply
came too late, post-mortem examinations revealed that a
substantial shrinkage of tumor mass had occurred. Further, all
patients demonstrated a significant reduction in pain within 12
to 24 hours of initiating the therapy.
What was
remarkable, however, is what happened to the rest of the
subjects. Again, and I cannot emphasize this too strongly, these
were all patients who were supposed to die. They had exhausted
every other alternative. Some were even comatose. They had no
hope, no chance for survival. But, despite the dire prognosis,
half of them did in fact survive.
Although further formal research in the United States was halted
shortly after the second human trial was concluded, thousands of
individuals, including this author, have employed the High pH
Therapy to fight their cancers. They provide a powerful
testimony to its effectiveness as well as a compelling rationale
for further formal research.
Back to Frequently Asked
Questions
|